Mackenzie Bourke presented “Incorporating individual-level preferences into cost-effectiveness analysis of population genomic risk screening: a discrete event simulation.”

Lizzy Liu presented “Risk in preferences for breast cancer genomic risk screening and subsequent prevention protocols.”

Julia Steinberg presented “Community preferences for population-wide genomic risk stratification (using polygenic risk scores) and risk-tailored cancer screening.”

📄 pubmed.ncbi.nlm.nih.gov/38459833/
📄 pubmed.ncbi.nlm.nih.gov/39725011/
humgenomics.biomedcentral.com/articles/10....

📄 pubmed.ncbi.nlm.nih.gov/35181209/
📄 nature.com/articles/s41...
📄 pubmed.ncbi.nlm.nih.gov/34099885/
📄 pubmed.ncbi.nlm.nih.gov/37489581/
📄 pubmed.ncbi.nlm.nih.gov/40172779/

Links to the papers referenced in the presentation are included below.
📄 pubmed.ncbi.nlm.nih.gov/32266555/
📄 pubmed.ncbi.nlm.nih.gov/39522058/
📄 pubmed.ncbi.nlm.nih.gov/32024983/
📄 pubmed.ncbi.nlm.nih.gov/32371919/
📄 nature.com/articles/s41...
📄 pubmed.ncbi.nlm.nih.gov/32839572/

Read more here: link.springer.com/article/10.1...

This systematic review highlights where genomic medicine is likely cost-effective across the cancer care continuum, from:
🔹 Prevention & early detection
🔹 Diagnosis, staging & planning
🔹 Treatment
🔹 Managing refractory/relapsed disease
🔹 Palliative & end-of-life care